Evidence map›Paper›PMID 36597530›Full record

ArticlebioRxiv : the preprint server for biology2022

Targeting Spike Glycans to Inhibit SARS-CoV2 Viral Entry.

Alex J Guseman, Linda J Rennick, Sham Nambulli, Chandra N Roy, David R Martinez, Darian T Yang, Fatema Bhinderwhala, Sandra Vergara, Ralph S Baric, Zandrea Ambrose and 2 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Alex J GusemanDepartment of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh PA, USA.
Linda J RennickCenter for Vaccine Research, University of Pittsburgh, Pittsburgh PA, USA.
Sham NambulliCenter for Vaccine Research, University of Pittsburgh, Pittsburgh PA, USA.
Chandra N RoyCenter for Vaccine Research, University of Pittsburgh, Pittsburgh PA, USA.
David R MartinezDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Darian T YangDepartment of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh PA, USA.
Fatema BhinderwhalaDepartment of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh PA, USA.
Sandra VergaraDepartment of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh PA, USA.
Ralph S BaricDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Zandrea AmbroseCenter for Vaccine Research, University of Pittsburgh, Pittsburgh PA, USA.
W Paul DuprexCenter for Vaccine Research, University of Pittsburgh, Pittsburgh PA, USA.
Angela M GronenbornDepartment of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh PA, USA.
University of Pittsburgh · USUniversity of North Carolina at Chapel Hill · US

Funding

Technology Development 2: MAS NMR and dynamic nuclear polarization for HIV-1 structural biologyP50AI150481 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GRONENBORN, ANGELA M. · 2019 to 2021
$14.1M
Project 3: Serological Interactions with the Mucosal Innate Immune System Regulates COVID-19 Associated Tissue Damage.U54CA260543 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARIC, RALPH S, WOLFGANG, MATTHEW C · 2020 to 2024
$9.8M
NCI NIH HHS U54 CA260543NIAID NIH HHS P50 AI150481
6 · The paper itself

Abstract

SARS-CoV-2 Spike harbors glycans which function as ligands for lectins. Therefore, it should be possible to exploit lectins to target SARS-CoV-2 and inhibit cellular entry by binding glycans on the Spike protein.

Identifiers

PMID36597530
PMCPMC9810211
OpenAlexW4312097261

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.